HEALTH-RELATED QUALITY OF LIFE AND MAPPED HEALTH UTILITY VALUES OF PATIENTS WITH ANKYLOSING SPONDYLITIS IN CHINA: A MULTICENTER REAL-WORLD STUDY
Author(s)
Jiaqi Shi, Master1, Xinyue Yuan, Bachelor1, Huifang Hu, PhD2, Yi Zhao, PhD3, MING HU, PhD1;
1West China School of Pharmacy, Sichuan University, Chengdu, China, 2Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China, 3Department of Rheumatology and Immunology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
1West China School of Pharmacy, Sichuan University, Chengdu, China, 2Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China, 3Department of Rheumatology and Immunology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
OBJECTIVES: This study aimed to assess the health-related quality of life (HRQoL) of patients with ankylosing spondylitis (AS) in China. It also compared health utility values (HUVs) obtained from generic preference-based measures with mapped utilities derived from AS-specific clinical measures.
METHODS: The data were obtained from a nationwide multicenter cross-sectional study survey conducted in 2024. The study received ethical approval from the China Clinical Trial Registry(ChiCTR2100054201). The survey provided 2,258 observations with complete BASDAI, BASFI, SF-36, and EQ-5D-5L responses covering the full range of disease severity. We first conducted descriptive analyses to summarize HRQoL among patients using different measures. Subgroup analyses were conducted based on disease severity and age groups. SF-36 reports were mapped to SF-6Dv1 using Generalized Measurement Mapping 1 (G-Map1) and Generalized Measurement Mapping 2 (G-Map2). Additionally, the study mapped BASDAI and BASFI to the EQ-5D-5L (DS-Map1) and SF-6Dv1 (DS-Map2) scales, based on published mapping algorithms. Subsequently, HUVs were calculated using the Chinese EQ-5D-5L and SF-6D value sets, and the different estimation methods were compared.
RESULTS: The mean (SD) HUV measured by EQ-5D-5L was 0.713 (0.239). The mean HUVs estimated by the four mapping methods ranged from 0.628 to 0.734 (G-Map1: 0.676 [SD 0.096], G-Map2: 0.709 [SD 0.087], DS-Map1: 0.684 [SD 0.187], DS-Map2: 0.628 [SD 0.010]). There were significant differences among the four indirect methods and between each of them and the direct EQ-5D-5L measurement (p<0.05). G-Map2 produced utilities (0.709±0.087) closest to EQ-5D-5L, DS-Map1 yielded the widest predicted range (0.085-0.982), whereas DS-Map2 generated highly concentrated estimates (0.549-0.696).
CONCLUSIONS: This study found that impairment in HUVs was severe among Chinese patients with AS; SF-6D-based mapping results were generally lower than EQ-5D-5L; and significant differences were observed in the mapped distributions based on BASDAI and BASFI, highlighting the need to develop more robust mapping methods.
METHODS: The data were obtained from a nationwide multicenter cross-sectional study survey conducted in 2024. The study received ethical approval from the China Clinical Trial Registry(ChiCTR2100054201). The survey provided 2,258 observations with complete BASDAI, BASFI, SF-36, and EQ-5D-5L responses covering the full range of disease severity. We first conducted descriptive analyses to summarize HRQoL among patients using different measures. Subgroup analyses were conducted based on disease severity and age groups. SF-36 reports were mapped to SF-6Dv1 using Generalized Measurement Mapping 1 (G-Map1) and Generalized Measurement Mapping 2 (G-Map2). Additionally, the study mapped BASDAI and BASFI to the EQ-5D-5L (DS-Map1) and SF-6Dv1 (DS-Map2) scales, based on published mapping algorithms. Subsequently, HUVs were calculated using the Chinese EQ-5D-5L and SF-6D value sets, and the different estimation methods were compared.
RESULTS: The mean (SD) HUV measured by EQ-5D-5L was 0.713 (0.239). The mean HUVs estimated by the four mapping methods ranged from 0.628 to 0.734 (G-Map1: 0.676 [SD 0.096], G-Map2: 0.709 [SD 0.087], DS-Map1: 0.684 [SD 0.187], DS-Map2: 0.628 [SD 0.010]). There were significant differences among the four indirect methods and between each of them and the direct EQ-5D-5L measurement (p<0.05). G-Map2 produced utilities (0.709±0.087) closest to EQ-5D-5L, DS-Map1 yielded the widest predicted range (0.085-0.982), whereas DS-Map2 generated highly concentrated estimates (0.549-0.696).
CONCLUSIONS: This study found that impairment in HUVs was severe among Chinese patients with AS; SF-6D-based mapping results were generally lower than EQ-5D-5L; and significant differences were observed in the mapped distributions based on BASDAI and BASFI, highlighting the need to develop more robust mapping methods.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR175
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Instrument Development, Validation, & Translation, Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)